Oramed Pharmaceuticals, Inc. (ORMP) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Protalix Biotherapeutics, Inc.

Gamida Cell Ltd.

Esperion Therapeutics, Inc.

Nektar Therapeutics

Annexon, Inc.

Talaris Therapeutics, Inc.

Oramed Pharmaceuticals, Inc.

Inovio Pharmaceuticals, Inc.

Reviva Pharmaceuticals Holdings, Inc.

Calidi Biotherapeutics, Inc.

Ocean Biomedical, Inc.

Why is Oramed Pharmaceuticals, Inc. ?

Unrated Stock - No Analysis Available

Real-Time Research Report

Verdict Report

No Data Found

Is Oramed Pharmaceuticals, Inc. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Oramed Pharmaceuticals, Inc.

98.16%

1.87

51.30%

S&P 500

20.78%

1.67

13.28%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-5.90%

EBIT Growth (5y)

-6.44%

EBIT to Interest (avg)

-19.08

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.93

Sales to Capital Employed (avg)

0.01

Tax Ratio

7.30%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

39.72%

ROCE (avg)

ROE (avg)

2.34%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

0.67

EV to EBIT

-0.55

EV to EBITDA

-0.55

EV to Capital Employed

0.11

EV to Sales

4.13

PEG Ratio

0.03

Dividend Yield

0.75%

ROCE (Latest)

-20.35%

ROE (Latest)

11.81%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

No Signal

Bearish

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bullish

OBV

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

10What is working for the Company

NET PROFIT(HY)

At USD -3.44 MM has Grown at 80.72%

ROCE(HY)

Highest at 57.61%

RAW MATERIAL COST(Y)

Fallen by -45.95% (YoY

-6What is not working for the Company

PRE-TAX PROFIT(Q)

At USD 4.63 MM has Fallen at -42.12%

NET PROFIT(Q)

At USD 3.59 MM has Fallen at -39.27%

DEBT-EQUITY RATIO (HY)

Highest at -27.31 %

Here's what is working for Oramed Pharmaceuticals, Inc.

Raw Material Cost

Fallen by -45.95% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Oramed Pharmaceuticals, Inc.

Pre-Tax Profit

At USD 4.63 MM has Fallen at -42.12%

over average net sales of the previous four periods of USD 8 MM

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Net Profit

At USD 3.59 MM has Fallen at -39.27%

over average net sales of the previous four periods of USD 5.91 MM

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (USD MM)

Debt-Equity Ratio

Highest at -27.31 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio